ALCON (NOVARTIS) CYPASS MICROSTENT FOR POA GLAUCOMA APPROVED BY FDA WHEN COMBINED WITH CATARACT SURGERY

CYPASS RESTS IN SUPRACILLIARY SPACE BETWEEN SCLERA AND CILIARY BODY,

NOT FOR USE IN ANGLE CLOSURE GLAUCOMA,

Marketed by ALCON , a Division of NOVARTIS. CyPass developed by TRANSCEND MEDICAL ,bought by ALCON in 2016.

NOVARTIS INTERNATIONAL AG has revenue US$ 50,4billion in 2015. Owns CIBA VISION, SANDOZ, ALCON & CHIRON Corp.

Stock: CHF 77.8 (2012 CHF 40)